Shanghai-based Dexter Yan is a senior writer covering China’s surging pharma industry on the APAC Pharma news team. With a keen interest in commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.
Latest From Dexter Yan
Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.
One initial public offering and six private funding deals add a total of $357m into the biotech funding pot in China as multiple new ventures look to progress pipeline assets and build capabilities.
The approval of China's second CAR-T therapy has come amid reimbursement challenges, despite the pricing of its direct competitor being much lower than in the US. Chinese developers are pinning their hopes on rapid domestic market expansion via commercial insurance tie-ups as other CAR-Ts move through local development.
Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
Hengrui’s second major in-licensing deal this year is the latest example of the Chinese pharma innovation darling’s eagerness for new assets, particularly as some of its other products come under pressure.